Publikacje
Influenza
- Van Damme P, et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009; 27:454-9;
- Della Cioppa G, et al. A dose-range study in older adults to compare the safety and immunogenicity profiles of MF59 adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration. Hum Vaccines Immunother 2014; 10:6, 1-10. Read full article.
- Levin Y, Kochba E, Kenney R. Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: Are all delivery methods the same? Vaccine 2014; 34:4249-52;
- Hung IF et al . Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccination. Vaccine 30 (2012) 2707– 2708. Read full article.
- Hung IF, et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine 2012; 30:6427-35;
- Levin Y. et al. A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly. Vaccine 34 (2016) 5262–5272. Read full article.
- Carter et al. The adjuvant GLA-AF enhances human intradermal vaccine responses. Sci. Adv. 2018; 4. eaas9930. Read full article.
- El Sahly HM, et al. Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered with Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults, The Journal of Infectious Diseases, Volume 224, Issue 10, 15 November 2021, Pages 1712–1719.
Polio
- Stephanie B. Troy et al. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults. J Infect Dis. (2015) 211 (12): 1969-1976. Read full article..
- Anand A et al. Early priming with inactivated poliovirus vaccine (IPV) andintradermal fractional dose IPV administered by a microneedledevice: A randomized controlled trial. Vaccine 33 (2015) 6816–6822
Zoster
- Chan R Beals et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infect Dis. 2016 Aug;16(8):915-22
HBV
- Hung IF et al. A Double-blind, Randomized Phase 2 Controlled Trial of Intradermal Hepatitis B Vaccination With a Topical Toll-like Receptor 7 Agonist Imiquimod, in Patients on Dialysis. Clin Infect Dis. 2020 Jun 18;ciaa804. doi: 10.1093/cid/ciaa804. Online ahead of print.
CMV
- Adler SP et al. Phase 1 Clinical Trial of a Conditionally Replication Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects. The Journal of Infectious Diseases® 2019;220:411–9. Read full article.
COVID
- Fan S, et al. Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine. Vaccine. 2021 Nov 26;39(48):6980-6983. Read full article.
- Levin Y. Peer review of: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,Qeios, December 22, 2021. Read full article.
Review
- Levin Y. et al. Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future. Human Vaccines & Immunotherapeutics 11:4, 991–997; April 2015
- Levin Y. et al. Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future. Human Vaccines & Immunotherapeutics 11:4, 991–997; April 2015
Skin Test
PPD
- Lee HJ et.al Safety and efficacy of tuberculin skin testing with microneedle MicronJet600 in healthy adults Int J Tuberc Lung Dis 20(4):500–504 Q 2016. Read full article.
Insulin
- Kochba E. et al. Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. Diabetes Technology & Therapeutics 2016; 18(9). Read full article.
Adalimumab
- Jacobse J et al. Comprehensive evaluation of microneedle-based intradermal adalimumab delivery versus subcutaneous administration: results of a randomized controlled trial. Br J Clin Pharmacol. 2021 Jan 5. doi: 10.1111/bcp.14729. Epub ahead of print. PMID: 33403697. Read full article.